



Technical Report No. 46

(Revised 2024)

**Last Mile: Guidance for Good
Distribution Practices for
Pharmaceutical Products to End
Users**



Last Mile: Guidance for Good Distribution Practices for Pharmaceutical Products to End Users

Authors and Contributors

Erik J. van Asselt, Ph.D., MSD (Co-Lead)

Rafik H. Bishara, Ph.D., Eli Lilly & Company (retired) (Co-Lead)

Riekert Bruinink, Former GDP Regulators

Junpei Cheng, EC Healthcare Fund

Giovanni Curotto, Epiqure

Fabian De Paoli, CCM28

Monika Derecque-Pois, GIRP

Ibnou Khadim Diaw, Africa Resource Centre Organization

Jean-Pierre Emond, The Illuminate Group

John Heller, Merck & Co., Inc.

Jeroen Janssens, Glaxo Smith Kline

Claude Jolicoeur, McKesson

Karl Kussow, FedEx

Zvonimir Majic, Technical Advisor

D. Mark Maurice, Sensitech

Janusz Mielewczyk, Amgen

Richard Peck, RP Pharma Consulting

Valentin Plouchard, EuropaBio - the European Association for Bioindustries

Marcia Alves Preda, Nordika

Jennifer Richards, URAC

Paul Rigby, Prioritise Ltd.

Anthony (TJ) Rizzo, Cold Chain Technologies

Lutz Schuette, Phoenix Group

Robert Seevers, Pearl Pathways

Eric Stener, Sanofi

Last Mile: Guidance for Good Distribution Practices for Pharmaceutical Products to End Users

Technical Report No. 46 (Revised 2024)

ISBN: 979-8-218-47790-5

© 2024 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 Introduction	1	5.5	Temperature-Monitoring During Transport	22
1.1 Purpose and Scope	1	5.5.1	Temperature-Monitoring or Data Loggers.....	22
2.0 Glossary and Abbreviations	1	5.5.2	Temperature Indicators	22
2.1 Abbreviations	3	5.5.3	Risk-Based Approach: Implementation and Management	23
3.0 Pharmaceutical Supply Chains	3	5.6	Security	23
3.1 Distribution in Supply Chains	3	6.0 Data and Knowledge Management.....	23	
3.2 Roles and Responsibilities in Supply Chains.....	5	6.1	Good Documentation Practices and Data Integrity	23
3.3 Supply Chains in Europe	6	6.1.1	Data Governance	24
3.4 Supply Chains in Africa.....	7	6.1.2	Good Documentation Practices.....	24
3.5 Supply Chains in Brazil.....	9	6.1.3	Data Integrity and Quality Management	25
3.6 Supply Chains in the United States	10	6.2	Temperature Management.....	26
3.7 Supply Chains in Canada	12	6.3	Other Critical Process Parameters	26
3.8 Supply Chains in China.....	13	6.4	Serialization	27
4.0 Pharmaceutical Products.....	15	6.4.1	Serialization in the European Union	27
4.1 Product Characteristics and Stability.....	15	6.4.2	Serialization in the United States	28
4.2 Application of Product Stability Budget and Mean Kinetic Temperature	15	6.5	Technologies	29
5.0 Services and Temperature Controlled Systems	17	6.5.1	Radio Frequency Identification Tag	29
5.1 Contract Management	17	6.5.2	Internet of Things	29
5.2 Storage.....	17	6.5.3	Blockchain.....	29
5.2.1 Storage Facilities	17	6.5.4	Machine Learning.....	30
5.2.2 Environmental Control	18	6.6	Management of Deviations and Complaints	31
5.3 Packaging	18	6.7	Performance Management.....	31
5.3.1 Packaging with Passive Thermal Functionality	19	6.8	Last-Mile Education.....	31
5.3.2 Packaging with Active Thermal Functionality	19	6.9	Good Distribution Practice Information for Healthcare Professionals (Dispensers)	32
5.3.3 Sustainability in Packaging .	20	6.10	Information to the Patient/Recipient	33
5.4 Transportation.....	20			
5.4.1 Road Transportation	20			
5.4.2 Drones	21			
5.4.3 Distribution from Point of Dispensing to End-Use in Mail Service Pharmacy.....	21			

7.0 Cost Management and Sustainability	34
7.1 Inventory Management	34
7.1.1 Rotating versus Stockpiling	34
7.1.2 Organizational and Administrative Reflections ..	35
7.2 Warehouse Storage and Temperature Control.....	35
7.3 Waste Stream for Packaging Components and Drug Product ..	35

7.3.1 Recycling and Regulations..	35
7.3.2 Reverse Logistics.....	36
7.4 Establishing Lowest-Cost Temperature-Control Solution for Shipment	37
7.5 Cost of Failure	37
7.5.1 Business Contingency Plan	38
8.0 Summary	38
9.0 References	39

Figures and Tables Index

Figure 3.1-1 Schematic Representation of the Pharmaceutical Supply Chain ...	4
Figure 3.4-1 Example of Pharmaceutical Supply Chain in Senegal.....	8
Figure 3.5-1 Example of Brazil's Supply Chain	9

Figure 3.6-1 Example of U.S. Private Sector Supply Chain	11
Figure 3.7-1 Map of Canada	12
Figure 6.5.3-1 Internet of Things Based Blockchain for Temperature Monitoring and Counterfeit Pharmaceutical Prevention.	30

1.0 Introduction

This guidance document complements the information provided in *PDA Technical Report No. 39 (Revised 2021): Guidance for Temperature-Controlled Medicinal Products — Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment* by going beyond manufacturer-focused issues and addressing issues specifically encountered within the “last mile” of the distribution of medicinal products and devices (1). This revision updates the original 2009 technical report to account for expanded regulations, the development and implementation of newer, more advanced technologies and supply chains that have become more extensive and complex (2).

1.1 Purpose and Scope

“Last mile” distribution is an often-used logistical term that refers to the transport of product from the manufacturing facility to the end user. For the purposes of this technical report, last mile is defined as the final transfer of a drug from the manufacturer or wholesaler to the end user which could be either the patient or the entity (e.g., pharmacy, hospital) that provides the drug to the patient. Transfers earlier in the distribution process involve organizations with greater knowledge of the product and the resources to ensure carefully controlled conditions of storage and transport compared to those available to the end user. As such, *PDA Technical Report No. 46 (Revised 2024): Last Mile: Guidance for Good Distribution Practices for Pharmaceutical Products to End User* provides recommendations and tools based on current best practices to ensure that product quality is maintained until the final handoff.

2.0 Glossary and Abbreviations

The Glossary includes a list of common terms specific to this technical report. Definitions of terms are listed alphabetically and may come from sources such as the U.S. Pharmacopeia, American Society for Testing Materials, International Conference for Harmonisation, International Organization for Standardization, or other PDA technical reports. Definitions quoted from other sources are cited at the end of the definition.

ALCOA+

ALCOA+ is an acronym standing for Attributable, Legible, Contemporaneous, Original, Accurate (“ALCOA”) and Complete, Consistent, Enduring and Available (“+”). It is a set of characteristics that all data must meet to ensure data integrity. Adherence to ALCOA+ principles is the basis for Good Documentation Practice.

Corrective Action, Preventive Action (CAPA)

Action to eliminate the cause of a detected nonconformity or other undesirable situation. Corrective action is taken to prevent recurrence, whereas preventive action is taken to prevent occurrence.

Customer

In distribution, the customer is the trading partner or reseller; in direct-to-consumer

situations, the customer is the end user who is either the patient taking the product or the person administering the product to the patient such as a physician.

Data Integrity

Data integrity is the degree to which data are complete, consistent, accurate, trustworthy, reliable and that these characteristics of the data are maintained throughout the data life cycle (3).

Downstream

Refers to the demand side of the supply chain that consists of one or more companies or individuals who participate in the flow of pharmaceuticals moving from the manufacturer to the end user.

Good Distribution Practices (GDP)

Defined as the part of quality assurance that ensures the quality of the pharmaceutical